JP7301815B2 - インターロイキン－１受容体アンタゴニスト融合タンパク質の送達による炎症状態の治療 - Google Patents

インターロイキン－１受容体アンタゴニスト融合タンパク質の送達による炎症状態の治療 Download PDF

Info

Publication number
JP7301815B2
JP7301815B2 JP2020516827A JP2020516827A JP7301815B2 JP 7301815 B2 JP7301815 B2 JP 7301815B2 JP 2020516827 A JP2020516827 A JP 2020516827A JP 2020516827 A JP2020516827 A JP 2020516827A JP 7301815 B2 JP7301815 B2 JP 7301815B2
Authority
JP
Japan
Prior art keywords
pericarditis
receptor
interleukin
composition
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020516827A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020535140A5 (https=
JP2020535140A (ja
Inventor
ジョン パオリーニ，
エベン テッサリ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2020535140A publication Critical patent/JP2020535140A/ja
Publication of JP2020535140A5 publication Critical patent/JP2020535140A5/ja
Priority to JP2023039474A priority Critical patent/JP7564270B2/ja
Application granted granted Critical
Publication of JP7301815B2 publication Critical patent/JP7301815B2/ja
Priority to JP2024110108A priority patent/JP2024133112A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2020516827A 2017-09-26 2018-09-26 インターロイキン－１受容体アンタゴニスト融合タンパク質の送達による炎症状態の治療 Active JP7301815B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023039474A JP7564270B2 (ja) 2017-09-26 2023-03-14 インターロイキン－１受容体アンタゴニスト融合タンパク質の送達による炎症状態の治療
JP2024110108A JP2024133112A (ja) 2017-09-26 2024-07-09 インターロイキン－１受容体アンタゴニスト融合タンパク質の送達による炎症状態の治療

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201762563387P 2017-09-26 2017-09-26
US62/563,387 2017-09-26
US201862616819P 2018-01-12 2018-01-12
US62/616,819 2018-01-12
US201862625075P 2018-02-01 2018-02-01
US62/625,075 2018-02-01
US201862639425P 2018-03-06 2018-03-06
US62/639,425 2018-03-06
US201862654291P 2018-04-06 2018-04-06
US62/654,291 2018-04-06
US201862691552P 2018-06-28 2018-06-28
US62/691,552 2018-06-28
US201862716331P 2018-08-08 2018-08-08
US62/716,331 2018-08-08
PCT/US2018/052985 WO2019067639A1 (en) 2017-09-26 2018-09-26 TREATMENT OF INFLAMMATORY CONDITIONS BY ADMINISTRATION OF INTERLEUKIN-1 RECEPTOR ANTAGONIST FUSION PROTEIN

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023039474A Division JP7564270B2 (ja) 2017-09-26 2023-03-14 インターロイキン－１受容体アンタゴニスト融合タンパク質の送達による炎症状態の治療

Publications (3)

Publication Number Publication Date
JP2020535140A JP2020535140A (ja) 2020-12-03
JP2020535140A5 JP2020535140A5 (https=) 2021-11-11
JP7301815B2 true JP7301815B2 (ja) 2023-07-03

Family

ID=63858163

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020516827A Active JP7301815B2 (ja) 2017-09-26 2018-09-26 インターロイキン－１受容体アンタゴニスト融合タンパク質の送達による炎症状態の治療
JP2023039474A Active JP7564270B2 (ja) 2017-09-26 2023-03-14 インターロイキン－１受容体アンタゴニスト融合タンパク質の送達による炎症状態の治療
JP2024110108A Pending JP2024133112A (ja) 2017-09-26 2024-07-09 インターロイキン－１受容体アンタゴニスト融合タンパク質の送達による炎症状態の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023039474A Active JP7564270B2 (ja) 2017-09-26 2023-03-14 インターロイキン－１受容体アンタゴニスト融合タンパク質の送達による炎症状態の治療
JP2024110108A Pending JP2024133112A (ja) 2017-09-26 2024-07-09 インターロイキン－１受容体アンタゴニスト融合タンパク質の送達による炎症状態の治療

Country Status (12)

Country Link
US (8) US11026997B2 (https=)
EP (2) EP3687562B1 (https=)
JP (3) JP7301815B2 (https=)
CA (1) CA3075538A1 (https=)
DK (1) DK3687562T3 (https=)
ES (1) ES3023044T3 (https=)
FI (1) FI3687562T3 (https=)
HU (1) HUE071206T2 (https=)
PL (1) PL3687562T3 (https=)
PT (1) PT3687562T (https=)
SI (1) SI3687562T1 (https=)
WO (1) WO2019067639A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3075538A1 (en) 2017-09-26 2019-04-04 Regeneron Pharmaceuticals, Inc. Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein
WO2026003765A1 (en) 2024-06-25 2026-01-02 Kiniksa Pharmaceuticals, Gmbh Formulations of anti-interleukin 1 receptor 1 antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060171948A1 (en) 2005-02-02 2006-08-03 Weinstein Steven P Methods of using IL-1 antagonists to reduce C-reactive protein

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012078101A1 (en) 2010-12-07 2012-06-14 Swedish Orphan Biovitrum Ab (Publ) Method for the treatment of il-1 mediated diseases
WO2014035361A1 (en) 2012-08-26 2014-03-06 R-PHARM, CJSC (Closed Joint Stock Company) IL-1β INHIBITOR COMPOSITION AND USE THEREOF
JP6225197B2 (ja) 2013-02-15 2017-11-01 アール−ファーム・ジョイント・ストック・カンパニーＲ−Ｐｈａｒｍ，Ｊｓｃ ＩＬ−１β阻害剤組成物およびその使用
WO2015147789A1 (en) 2014-03-24 2015-10-01 R-Pharm Overseas, Inc. Human il 1-r1 derived inhibitor of il-1b
CA3075538A1 (en) 2017-09-26 2019-04-04 Regeneron Pharmaceuticals, Inc. Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060171948A1 (en) 2005-02-02 2006-08-03 Weinstein Steven P Methods of using IL-1 antagonists to reduce C-reactive protein

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANTONIO BRUCATO，JAMA / THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION，米国，2016年11月08日，VOL:316, NR:18,，PAGE(S):1906-1912，http://dx.doi.org/10.1001/jama.2016.15826
BENJAMIN W VAN TASSELL，TARGETING INTERLEUKIN-1 IN HEART DISEASE，CIRCULATION，米国，2013年10月22日，VOL:128, NR:17,，PAGE(S):1910 - 1923，http://dx.doi.org/10.1161/CIRCULATIONAHA.113.003199
MARIA JAWORSKA-WILCZYNSKA，POST-CARDIAC INJURY SYNDROME，POLISH JOURNAL OF CARDIO-THORACIC SURGERY，2013年，VOL:10, NR:1,，PAGE(S):20 - 26，http://dx.doi.org/10.5114/kitp.2013.34299

Also Published As

Publication number Publication date
US20220072102A1 (en) 2022-03-10
EP3687562A1 (en) 2020-08-05
EP3687562B1 (en) 2025-03-19
US20240293510A1 (en) 2024-09-05
DK3687562T3 (da) 2025-04-14
JP7564270B2 (ja) 2024-10-08
US20210283224A1 (en) 2021-09-16
ES3023044T3 (en) 2025-05-29
EP4541367A3 (en) 2025-07-30
US11464830B2 (en) 2022-10-11
SI3687562T1 (sl) 2025-06-30
US20220409699A1 (en) 2022-12-29
US12201673B2 (en) 2025-01-21
WO2019067639A1 (en) 2019-04-04
JP2024133112A (ja) 2024-10-01
PT3687562T (pt) 2025-04-03
EP4541367A2 (en) 2025-04-23
HUE071206T2 (hu) 2025-08-28
US20250345396A1 (en) 2025-11-13
US20230012740A1 (en) 2023-01-19
US20230346887A1 (en) 2023-11-02
US20190151417A1 (en) 2019-05-23
JP2020535140A (ja) 2020-12-03
CA3075538A1 (en) 2019-04-04
US11026997B2 (en) 2021-06-08
US11844765B2 (en) 2023-12-19
JP2023063426A (ja) 2023-05-09
US11944666B2 (en) 2024-04-02
FI3687562T3 (fi) 2025-04-25
PL3687562T3 (pl) 2025-05-12

Similar Documents

Publication Publication Date Title
US20250345396A1 (en) Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein
WO2018075658A1 (en) Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction
US20250236676A1 (en) TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRBeta ANTIBODY
JP7495403B2 (ja) 巨細胞性動脈炎の治療
TW202423972A (zh) 使用抗介白素－３３抗體的氣喘治療
HK40035543B (en) Treatment of recurrent idiopathic pericarditis by delivery of interleukin-1 receptor antagonist fusion protein
HK40035543A (en) Treatment of recurrent idiopathic pericarditis by delivery of interleukin-1 receptor antagonist fusion protein
WO2020096664A1 (en) Treatment for giant cell arteritis
WO2025124760A1 (en) Treatment of subpopulation of patients with rheumatoid arthritis
JP2008509989A (ja) 乾癬症の治療におけるｔｎｆ結合タンパク質−１

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210924

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220914

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230314

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230609

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230621

R150 Certificate of patent or registration of utility model

Ref document number: 7301815

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150